RxDoctor Payments Data

Sarah Ashitey, MD

Family Medicine · Dallas, TXNPI 1851681456

Payments from drug & device makers

$9,722in general payments, 2019–2025

Across 458 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shield Therapeutics Inc$1K
  • Novo Nordisk$808
  • Gilead$690
  • Lilly USA, LLC$626
  • AbbVie$614
  • GSK$570
  • plus $5K from 41 others

What the payments were for

  • Speaking & faculty fees$1,22013%
  • Food & beverage$8,41787%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,722 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$26,822
Medicare patients
52
Services billed
303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide24$49,154
OzempicSemaglutide29$42,622
FarxigaDapagliflozin Propanediol27$37,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$32,885
MounjaroTirzepatide22$29,580
TrulicityDulaglutide20$22,073
JardianceEmpagliflozin23$21,849
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,989
EliquisApixaban13$12,561
ButransBuprenorphine13$7,018
SymbicortBudesonide/Formoterol Fumarate13$4,029
Dexlansoprazole DrDexlansoprazole12$2,179
Atorvastatin Calcium182$1,390
Amlodipine Besylate146$1,231
Albuterol Sulfate HfaAlbuterol Sulfate43$1,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$808$91,77753 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$452$56,00562 claims
Lilly USA, LLCMounjaro, Trulicity$626$51,65342 claims
GSKTrelegy Ellipta$570$32,88537 claims
Boehringer IngelheimJardiance$247$21,84923 claims
PfizerEliquis$479$12,56113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →